impact of PV on PE

[Guest guest]

Hi,

Medecines Sans Frontieres (MSF) does medicine pricing research, output of which

is utilized by them in procurement of medicines.

Currently MSF is providing medical assistance to populations in distress in >80

countries.

Vijay

>

> hello,

> I asked a question in my earlier post about any organization which manages all

data on research conducted in a country. What is the need of such management of

data? Obviously for policy reforms.

> Data on health outcomes is required to develop monitor and evaluate

pharmaceutical policy. Pharmacoeconomic evaluation is a new tool used by several

countries (Australia, Canada Finland, Norway UK and The Netherlands) in decision

making process. The most developed tool is that adopted by Australia which is a

two step process.

> 1 an in depth review by a team with skills in clinical  epidemiology,

biostatistics and health economics, and

> 2.a concise overview by independent technical committee with the same three

skills,

>  making the decision making process very effective.

> This is what we mean by putting research into practice, on a national scale. 

> kunda

>  

>

[Guest guest]

Hi

And the reverse is also true. Regulatory authorities of some countries ignore

the global ADR reports and claim that the medicines banned in other countries is

safe for their population e.g. Nimesulide in India.

Vijay

>

> hello,

> Direct impact of PV on PE

> In order to assess the potential magnitude of the problem,(ADR) it is

 necessary to relate the number of case reports or to the number of patients

exposed. If it is possible to detect that a certain adverse reaction is more

common in a certain age group/condition/at a special dose level, improving the

information on proper use such as indications, contraindications and appropriate

dosages may be sufficient to assure a safer use. Thereby withdrawal of the drug

from the market may be avoided.

> More to come later.

> kunda

>

[Guest guest]

hello All,

it is very true that some organisations like MSF are using epidemiological data for policy framing as mentioned by Vijay.He also mentioned the denial practise of Indian policy framers to the reports of global epidemiological study on Nimesulide.

What we need to improve is to follow the good works of countries like Australia which has shown how PV can be used along with PE in deciding upon the health economy.

kunda

From: Vijay <drvijaythawani@...>Subject: Re: impact of PV on PEnetrum Date: Monday, 17 May, 2010, 12:04 PM

HiAnd the reverse is also true. Regulatory authorities of some countries ignore the global ADR reports and claim that the medicines banned in other countries is safe for their population e.g. Nimesulide in India.Vijay >> hello,> Direct impact of PV on PE> In order to assess the potential magnitude of the problem,(ADR) it is necessary to relate the number of case reports or to the number of patients exposed. If it is possible to detect that a certain adverse reaction is more common in a certain age group/condition/at a special dose level, improving the information on proper use such as indications, contraindications and appropriate dosages may be sufficient to assure a safer

use. Thereby withdrawal of the drug from the market may be avoided.> More to come later.> kunda>

[Guest guest]

I agree in principle with PE but its irritating to know that in hospitals salary budget is highest and no one thinks whether it is utilised efficiently. Cost of drugs is cheapest in India and still we want to cut it. I think aim of PE is better utilisation of available funds and not reducing the requirement of funds. This concept should be clear in our mind.DG ShewadeProfessor of PharmacologyJIPMER, Pondicherry 605006, India Mob 9843868212From: kunda gharpure <gharpurekunda@...>Subject: impact of PV on PETo:

netrum Date: Monday, 17 May, 2010, 1:00 PM

hello,

to contunue with the dicussion further-

How health economists calculate the costs to society of drug-related problems As drugs become an increasingly prominent item in health budgets, physicians are increasingly under pressure for controlling costs; pharmacovigilance is gaining importance in addressing health costs. The management of HIV/AIDS in developing countries is illustrative of these issues. Antiretroviral treatment regimens involve two or three potentially toxic agents. Monitoring safety and efficacy involves regular laboratory testing of liver function, hematology, viral resistance by CD4 cell count and viral load. Furthermore, treatment of the serious and not uncommon adverse effects of such treatment, like dermatological, hepatic, hematological, metabolic and neurological disturbances, adds further to the health budget. As such when considering the cost of disease to

society or an individual, ADRs and what is spent on detecting, preventing and managing them also needs to be included in the analysis.

One more field for PV to join hands with PE

kunda

[Guest guest]

hello,

Yes we agree in principle that the heads other than medicines in a hospital budget consume more funds. we also are aware that the medicines in India are cheaper in comparison to other countries. but the problem is of affordability in terms of daily income of the people which is way behind the other economically developed countries. Eg if a person in developed nations is required to pay from his pocket ,he would lose at the most half a days wages to treat himself . As against this In developing nations the patient loses about 15days wages. This is only an example to make the point clear. PE

kunda is useful at the macro economic level where data is used to allocate the annual budget of a country for health sector.

From: kunda gharpure <gharpurekunda@ .co. in>Subject: impact of PV on PEnetrumgroups (DOT) comDate: Monday, 17 May, 2010, 1:00 PM

hello,

to contunue with the dicussion further-

How health economists calculate the costs to society of drug-related problems

As drugs become an increasingly prominent item in health budgets, physicians are increasingly under pressure for controlling costs; pharmacovigilance is gaining importance in addressing health costs. The management of HIV/AIDS in developing countries is illustrative of these issues. Antiretroviral treatment regimens involve two or three potentially toxic agents. Monitoring safety and efficacy involves regular laboratory testing of liver function, hematology, viral resistance by CD4 cell count and viral load. Furthermore, treatment of the serious and not uncommon adverse effects of such treatment, like dermatological, hepatic, hematological, metabolic and neurological disturbances, adds further to the health budget. As such when considering the cost of disease to society or an individual, ADRs and

what is spent on detecting, preventing and managing them also needs to be included in the analysis.

One more field for PV to join hands with PE

kunda

[Guest guest]

Dear Dr Kunda,When poor patient is required to pay from his pocket he is at the mercy of the prescriber. She / He does not have the information regarding which drugs to be given priority or generic cheaper substitute will serve the purpose. This type of incomplete drug therapy leads to treatment failure. Some drugs are so cheap that pharmacist does not find it economical to stock. PE is used at very limited extent only in government teaching hospitals. Pharmacists at the counter has wide scope in this area and by making available relevant drug information, he is going to make appreciable service to patients. Application of PE is beneficial to all, earlier we recognise, better it is.Therefore I feel we should decimate PE information on as many plate-forms as possible.DG

ShewadeProfessor of PharmacologyJIPMER, Pondicherry 605006, India Mob 9843868212

From: kunda gharpure <gharpurekunda@ .co. in>Subject: impact of PV on PEnetrumgroups (DOT) comDate: Monday, 17 May, 2010, 1:00 PM

hello,

to contunue with the dicussion further-

How health economists calculate the costs to society of drug-related problems As drugs become an increasingly prominent item in health budgets, physicians are increasingly under pressure for controlling costs; pharmacovigilance is gaining importance in addressing health costs. The management of HIV/AIDS in developing countries is illustrative of these issues. Antiretroviral treatment regimens involve two or three potentially toxic agents. Monitoring safety and efficacy involves regular laboratory testing of liver function, hematology, viral resistance by CD4 cell count and viral load. Furthermore, treatment of the serious and not uncommon adverse effects of such treatment, like dermatological, hepatic, hematological, metabolic and neurological disturbances, adds further to the health budget. As such when considering the cost of disease to society or an individual, ADRs and

what is spent on detecting, preventing and managing them also needs to be included in the analysis. One more field for PV to join hands with PE kunda

[Guest guest]

Hello,

Dr Deepak Shewade in his post laments about the lack of information to the patients. In my earlier post today I mentioned about the third arm of the health sector, ie. the information system. And I also mentioned that for the economy to be on the right track, the information dissemination is equally important.The same thought is rightly put forth by Deepak and I am happy to note that on this Netrum platform we have several such like minded people.

kunda

From: kunda gharpure <gharpurekunda@ .co. in>Subject: impact of PV on PEnetrumgroups (DOT) comDate: Monday, 17 May, 2010, 1:00 PM

hello,

to contunue with the dicussion further-

How health economists calculate the costs to society of drug-related problems

As drugs become an increasingly prominent item in health budgets, physicians are increasingly under pressure for controlling costs; pharmacovigilance is gaining importance in addressing health costs. The management of HIV/AIDS in developing countries is illustrative of these issues. Antiretroviral treatment regimens involve two or three potentially toxic agents. Monitoring safety and efficacy involves regular laboratory testing of liver function, hematology, viral resistance by CD4 cell count and viral load. Furthermore, treatment of the serious and not uncommon adverse effects of such treatment, like dermatological, hepatic, hematological, metabolic and neurological disturbances, adds further to the health budget. As such when considering the cost of disease to society or an individual, ADRs and

what is spent on detecting, preventing and managing them also needs to be included in the analysis.

One more field for PV to join hands with PE

kunda

[Guest guest]

hello,.

a concise chart depicting relationship of different branches in medicicine research and its application is attached

kunda